New FDA Approvals and Updates
Femlyv: A New Birth Control Option
FDA Approval: On Monday, the FDA approved Femlyv (norethindrone acetate and ethinyl estradiol), the first orally disintegrating tablet for preventing pregnancy. This offers a new option for those who have difficulty swallowing pills.
Key Details:
- Active Ingredients: Norethindrone acetate and ethinyl estradiol.
- Previous Approval: These ingredients have been in use since 1968 in swallowable tablets.
- Target Audience: Individuals with difficulty swallowing.
Common Side Effects:
- Headache
- Vaginal candidiasis
- Nausea
- Menstrual cramps
- Breast tenderness
- Bacterial vaginitis
- Acne
- Mood swings
- Weight gain
For full prescribing information, consult the official FDA documentation.
Laboratory Developed Tests (LDTs)
Transparency Initiative: The FDA is enhancing transparency by addressing common questions about LDTs. Updates will be provided via webinars, guidances, an FAQ page, and other resources during the phaseout of general enforcement discretion for LDTs.
Influenza Diagnostic Tests:
- Update: LDTs for Highly Pathogenic Avian Influenza (HPAI) are under the FDA’s general enforcement discretion.
- No Marketing Authorization Required: CLIA-certified labs qualified for high-complexity testing do not need FDA marketing authorization for these LDTs.
For questions not answered on the FAQ page, contact the FDA at ldtfinalrule@fda.hhs.gov.
Quality and Performance of Medical Devices
Warning Letters Issued:
- Jiangsu Shenli Medical Production Co., Ltd.: Expanded import alert for quality system violations in syringe products.
- Jiangsu Caina Medical Co. Ltd.: Quality system violations leading to an import alert for their enteral syringes.
Recommendation: Transition away from using enteral syringes from these manufacturers unless absolutely necessary.
Upcoming FDA Workshop
Event: Accreditation Scheme for Conformity Assessment (ASCA) and Chemical Analysis for Biocompatibility of Medical Devices workshop.
- Date: Wednesday, November 6, 2024
- Location: FDA’s White Oak campus, Silver Spring, Md.
- Webcast: Available in listen-only mode.
- Registration Deadline: October 30, 2024
- Comments Submission Deadline: December 6, 2024
E-Cigarette Product Authorization
Marketing Authorization: The FDA authorized seven e-cigarette products from R.J. Reynolds Vapor Company, including the Vuse Alto Power Unit and six Vuse Alto tobacco-flavored pods.
Note: Authorization does not mean these products are safe or FDA approved.
Recent FDA Publications
Men’s Health Concerns
Article: “Catching Up with Califf: Men’s Health is Falling Behind – Some Thoughts About Why” by Robert M. Califf, M.D., FDA Commissioner.
- Focus: Decline in men’s health and underlying reasons.
Rare Disease Innovation
Announcement: Establishment of a Rare Disease Innovation Hub.
- Goal: Enhance and advance outcomes for patients with rare diseases.
Chronic Disease Awareness
Article: “From Awareness to Action: Tackling the Rising Burden of Common Chronic Diseases” by Robert M. Califf, M.D.
- Focus: Addressing the impact of chronic diseases on life expectancy.
Pediatric Inflammatory Bowel Disease (IBD) Guidance
Draft Guidance: For the development of drugs to treat pediatric IBD, including ulcerative colitis and Crohn’s disease.
- Focus: Study design, population, efficacy considerations, and safety assessments.
Home as a Health Care Hub Initiative
Virtual Public Meeting: Discussing home integration into the health care system.
- Date: Thursday, July 25, from 12-4 p.m. ET
- Registration Deadline: July 25, 11 a.m. ET
..
Need Help Navigating These Updates?
Garg Law is here to assist you with understanding and complying with these FDA changes. Our expertise in FDA regulations ensures you stay compliant and informed.
Contact Us today for tailored legal advice and support.
Read the full FDA article here.